InVivo Therapeutics Holdings Corp. (NVIV) Reached 12-Month Low on Jun, 29 at $1.73

June 29, 2018 - By Matthew Medley

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Corporate Logo

Today InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) with $1.73 price per share, touched 1-year low with $1.63 PT or 6.00 % below. On Jun, 29 the 1-year low was announced by Barchart.com. The company has $3.52 million market cap. $211,440 less could be NASDAQ:NVIV valuation at $1.63 share price.

NVIV touched $1.73 during the last trading session after $0.02 change.InVivo Therapeutics Holdings Corp. has volume of 58,361 shares. Since June 29, 2017 NVIV has declined 86.50% and is downtrending. The stock underperformed the S&P 500 by 99.07%.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s earnings release is anticipated by WallStreet on August, 14, according to Faxor. This year’s EPS analyst estimate is anticipated to be $-3.25. That is 35.00 % up compareed to $-5 EPS for last year. Analysts at Wall Street see InVivo Therapeutics Holdings Corp.’s -2.69 % EPS growth compared to $-3.34 EPS for previous quarter.

For more InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) news posted briefly go to: Benzinga.com, Benzinga.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” posted on June 21, 2018, “60 Biggest Movers From Yesterday” on June 19, 2018, “40 Biggest Movers From Friday” with a publish date: June 18, 2018, “50 Biggest Movers From Yesterday” and the last “30 Stocks Moving In Thursday’s Pre-Market Session” with publication date: June 21, 2018.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries .The firm is valued at $3.52 million. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI.Last it reported negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.